



SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Istituto di Ricovero e Cura a Carattere Scientifico

ISTITUTO
ROMAGNOLO
PER LO STUDIO
DEI TUMORI
DINO AMADORI

Con il patrocinio di



MYELOFIBROSIS:

facing the future by challenging the past (4th ed)

Forlì, 10-11 November 2023

Aurora APS (ex Circolo della Scranna)

Scientific Director: Alessandro Lucchesi

ISCRIZIONE

L'iscrizione si effettua scaricando l'app "DEEP ECM", in seguito alla registrazione, inserire le proprie credenziali ed il PIN dell'evento "MYELOFIBROSIS" Maggiori info al link www.proeventi.it.

ECM

Evento RES n. 2773- 393075
Obiettivo 3
9 crediti ECM per
Medici (tutte le specialità)
Infermieri
Farmacisti
Biologi
TLSB



PROVIDER

PROEVENTI SRL
PROVIDER N.2773
info@proeventi.it
www.proeventi.it

SCIENTIFIC PROGRAM

FRIDAY NOV. 10, 2023

14:00
Welcome Coffee

14:30
Welcome and introduction
A. Lucchesi, G. Martinelli, G. Musuraca

Special session
14:40 - 15:50
POST-PANDEMIC, VACCINES AND AI: WHAT IDEAS TO GATHER AND DEVELOP FOR MPNS?
Chair C. Cerchione, N. Gentili

14:40
Cancer vaccines: general concepts and advances on their development in MPNs
M.O. Holmstrom

15:00
Three years of pandemic: useful lessons for managing MPNs
G. Giordano

15:20
Artificial intelligence and possible opportunities in hematology
F. Gori

15:45 Discussion

15:55
LECTURE Chair A. Lucchesi
The evolving concept of disease modification in myelofibrosis
N. Pemmaraju

16:20 - 17:10
PRECLINICAL SESSION
The biological basis of targeted therapies in myelofibrosis
Chair G. Martinelli, G. Simonetti

16:20
New tools for validation of therapeutic targets in myelofibrosis
J. O'Sullivan

16:45
Persistence of mutated JAK clones and possible mechanisms of inhibitor resistance
F.H. Heidel

17:10 Coffee break

17:20 - 18:10
SESSION ON INTEGRATIVE APPROACHES
The importance of managing hypercoagulable states
Chair G. Giordano, L. Catani

17:20
Impaired endothelial function and coagulation: not sideline implications but key pathogenic promoters
A. Lucchesi

17:45
Prediction, prophylaxis, and treatment of vascular events
G. Micucci

18:15 - 19:50
CLINICAL SESSION 1
First landfalls for the management of clinical manifestations
Chair: G. Rosti, H.K Al-Ali

18:15
Early treatment with JAK inhibitors: reasons, choices and evidence
M. Tiribelli

18:40
The anemic MF patient: new strategies to improve outcomes
B. Mora

19:05
Clinical burden, prognostic implication and management of thrombocytopenia in MF
C. Di Pietro

19:30 Closing remarks

SATURDAY NOV. 11, 2023

8:50
Introduction to Day 2
A. Lucchesi, G. Micucci, M. Poggiaspalla, F. Frabetti

9:00 - 11:05
CLINICAL SESSION 2
Cytopenias, resistance, dismal prognosis: the main challenges
Chair F. Lanza, G. Musuraca

9:00
Myelofibrosis and targetable pathways: where are we now, and where are we going?
J.J. Kiladjian

9:25
Current positioning of different JAK2 inhibitors and their switching
P. Guglielmelli

9:50
New prognostic models and decision-making arising from the extensive use of JAK2 inhibitors
G.A. Palumbo

10:15
Transplantation in the era of novel therapies: how to preserve an opportunity
N. Gagelmann

10:40
Tackling fibrosis and inflammation, between fact and assumptions
E. Masselli

11:05 Coffee break

11:20 - 13:00
NEW DRUGS SESSION
Rationale and preliminary data of novel compounds for myelofibrosis
Chair J.J. Kiladjian, G.A. Palumbo

11:20
Inhibition of BET proteins and epigenetic modulators
H.K. Al-Ali

11:45
Pro-apoptotic agents: alone or in a combo?
A. Patriarca

12:10
Drugs with multikinase activity
S. Tantravahi

12:40 - 13:30
FINAL SPECIAL LESSONS DEEPER INTO COMPLEXITY
Chair F. Malaspina, M.Poggiaspalla

12:40
Myelofibrosis and autoimmunity
C. Baraté

13:05
AI applications supporting the MPNs community
F. Gori

13:30
Closing remarks and introduction to the 5th ed.
A. Lucchesi, G. Musuraca

RATIONALE

The 4th edition of the Myelofibrosis Congress, titled "Facing the Future by Challenging the Past," is a highly anticipated scientific gathering that aims to drive advancements in myelofibrosis research and treatment. With a focus on innovation and progress, this congress will bring together esteemed experts in the field, fostering collaborative discussions and knowledge sharing.

The congress will delve into various critical topics that are at the forefront of myelofibrosis research. Translational research will take center stage, exploring the latest findings in molecular biology, genomics, and epigenetics. By unraveling the underlying mechanisms of myelofibrosis, researchers aim to pave the way for the development of more effective therapeutic interventions.

Biomarkers will be a key area of discussion, with researchers presenting advancements in molecular, genetic, and imaging biomarkers associated with myelofibrosis. The focus will be on refining diagnostic accuracy, improving risk stratification, and enabling personalized treatment strategies. These advancements hold great potential for enhancing patient care and outcomes.

The congress will also highlight current approaches for managing the clinical manifestations of myelofibrosis. By addressing symptomatic relief strategies, including supportive care measures and pain management, experts aim to improve the quality of life for individuals living with myelofibrosis.

Novel therapies will be a significant area of interest, showcasing the latest developments in targeted treatments, immunomodulatory agents, and combination therapies. Clinical trial results, real-world evidence, and emerging therapeutic targets will be presented, fostering collaborations to accelerate the implementation of these promising approaches.

Furthermore, the integration of artificial intelligence (AI) into myelofibrosis research and clinical practice will be explored. Researchers will discuss the applications of machine learning algorithms, natural language processing, and image analysis in improving diagnosis, treatment prediction, and personalized medicine for myelofibrosis patients. Ethical considerations and challenges associated with AI integration will also be addressed.

The Myelofibrosis Congress serves as a platform for experts to come together, exchange ideas, and advance the understanding and management of myelofibrosis. By fostering collaboration and innovation, the congress aims to drive progress in the field, ultimately improving patient outcomes and quality of life. Participants will have the opportunity to engage in meaningful discussions, share valuable insights, and contribute to shaping the future of myelofibrosis research and treatment.

FACULTY

AL-ALI HAIFA KATHRIN HALLE, GERMANIA

BARATE' CLAUDIA PISA

CATANI LUCIA BOLOGNA

CERCHIONE CLAUDIO MELDOLA (FC)

DI PIETRO CHRISTIAN RIMINI

FRABETTI FEDERICA MELDOLA (FC)

GAGELMANN NICO AMBURGO, GERMANIA

GENTILI NICOLA MELDOLA (FC)

GIORDANO GIULIO CAMPOBASSO

GORI FABIO L'AIA, OLANDA

GUGLIELMELLI PAOLA FIRENZE

HEIDEL FLORIAN GREIFSWALD, GERMANIA

HOLMSTROM MORTEN O. HERLEV, DANIMARCA

K. TANTRAVAHU SRINIVAS SALT LAKE CITY, UT

KILADIJAN JEAN JACQUES PARIGI

LANZA FRANCESCO RAVENNA

LUCCHESI ALESSANDRO MELDOLA (FC)

MALASPINA FRANCESCO MELDOLA (FC)

MARTINELLI GIOVANNI MELDOLA

MASSELLI ELENA PARMA

MICUCCI GIORGIA MELDOLA (FC)

MORA BARBARA MILANO

MUSURACA GERARDO MELDOLA (FC)

O' SULLIVAN JENNIFER OXFORD, INGHILTERRA

PALUMBO GIUSEPPE ALBERTO CATANIA

PATRIARCA ANDREA NOVARA

PEMMARAJU NAVEEN HOUSTON, TX

POGGIASPALLA MONICA MELDOLA (FC)

ROSTI GIANANTONIO MELDOLA (FC)

SIMONETTI GIORGIA MELDOLA (FC)

TIRIBELLI MARIO UDINE

ISCRIZIONE

L'iscrizione si effettua scaricando l'app "DEEP ECM", in seguito alla registrazione, inserire le proprie credenziali ed il PIN dell'evento "MYELOFIBROSIS"

Maggiori info al link www.proeventi.it

SALA CONGRESSUALE

Associazione Aurora A.P.S. Forlì,
Corso Garibaldi 80 (Palazzo Albicini)

PROVIDER



PROEVENTI SRL
PROVIDER N.2773
info@proeventi.it
www.proeventi.it

ECM

Evento RES n. 2773- 393075
Obiettivo 3

9 crediti ECM per

- Medici (tutte le specialità)
- Infermieri
- Farmacisti
- Biologi
- TLSB

QUESTIONARIO E ATTESTATO

Saranno disponibili online accedendo tramite APP DEEP ECM - PIN: MYELOFIBROSIS

Ai fini dell'acquisizione dei crediti formativi è **INDISPENSABILE** la presenza effettiva al 90% della durata complessiva dei lavori e almeno il 75% delle risposte corrette al questionario di valutazione dell'apprendimento.

La compilazione del questionario darà diritto ai crediti SOLO se associata alla verifica dell'effettiva presenza all'evento.

La scadenza per la compilazione del questionario di valutazione ECM è fissata entro le 72 ore dalla fine del corso.

Con il contributo educativo non condizionante di

